acute graft versus host disease

December 5, 2019December 10, 2019

Orencia Given FDA’s Breakthrough Status as Treatment to Prevent Graft-versus-Host Disease After Stem Cell Transplant

News

Bristol-Myers Squibb‘s arthritis medicine Orencia (abatacept) has been named Breakthrough Therapy by the U.S. Food and Drug Administration for the prevention of acute graft-versus-host disease (GvHD) in patients who received ... Read more

February 28, 2018February 28, 2018

Age Alone Shouldn’t Exclude Non-Hodgkin’s Lymphoma Patients from Stem Cell Transplants, Study Finds

News

When choosing which patients are eligible for blood stem cell transplants, age is usually one of the factors weighed in. Now, a new study shows that at least for patients ... Read more

August 19, 2016August 19, 2016

T-cell Lymphoma/Leukemia Patients Eligible for HSCT Cautioned on Use of Poteligeo

News

Patients with adult T-cell leukemia/lymphoma (ATLL) who were treated with Poteligeo (mogamulizumab), an anti-CCR4 monoclonal antibody, may be at higher risk for serious graft-versus-host disease (GvHD)-related complications following allogeneic hematopoietic stem ... Read more

May 27, 2016August 23, 2016

New Immunotherapy for Stem Cell Transplant to be Introduced at Biotechnology Convention

News

Xenikos B.V. will discuss its lead product candidate T-Guard, designed for acute graft versus host disease (GVHD), at the BIO International Convention 2016, June 6-9, in San Francisco, Calif. Transplantation of allogenic (donor-derived) ... Read more